


→  **TYPE 3**  
JUN 10 2005  
**DISCLOSURE**  
**APPLICANT**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

<b>Complete if Known</b>	
Application Number	09/838,987
Filing Date	Apr. 20, 2001
First Named Inventor	CHAMBERLAIN et al.
Group Art Unit	1632
Examiner Name	Michael C. Wilson
Attorney Docket Number	218654
Client Reference No.	E-087-1996/0-US-05

Sheet	1	of	1
-------	---	----	---

[illegible][illegible]

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
WV	AS	FRANCHINI et al., <i>AIDS Res. Hum. Retroviruses</i> , 11(8), 909-920 (1995)		
WV	AT	IRVINE et al., <i>Vaccine Res.</i> , 2(2), 79-94 (1993)		
WV	AU	LEONG et al., <i>Vaccines</i> , 95, 327-331 (1995)		
WV	AV	RODRIGUES et al., <i>J. Immunol.</i> , 153, 4636-4648 (1994)		



10-27-04

- + An English-language equivalent patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).